secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2024-08-20T23:59:59+00:00
Accession:  0001193125-24-203755
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera prices $225M offering of common stock and pre-funded warrants
--------------------------------------------------------------------

- Selling 2,002,313 shares at $40.75 and 3,519,159 pre-funded warrants at $40.7499.
- Net proceeds estimated at ~$246.5M after underwriting discounts and expenses.
- Underwriters exercised 30-day option to purchase additional 828,220 shares in full.
- Proceeds to advance preclinical and clinical degrader programs and for working capital.
- Existing cash plus offering proceeds expected to fund operations into mid 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312524203755/0001193125-24-203755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312524203755/d846843d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-203755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer